This topic contains a solution. Click here to go to the answer

Author Question: The horizontal component of the buttressing force at the base of a pointed arch is A) less ... (Read 68 times)

corkyiscool3328

  • Hero Member
  • *****
  • Posts: 539
The horizontal component of the buttressing force at the base of a pointed arch is
 
  A)
 
  less than that of a rounded arch.
 
  B)
 
  equal to that of a rounded arch.
  C)
 
  greater than that of a rounded arch.
 
  D)
 
  zero in magnitude.

Question 2

A sound source emits 30.0 W of sound power spread equally in all directions. What is the sound intensity level 30.0 m from the source?
 
  A)
 
  94.2 dB
  B)
 
  83.2 dB
  C)
 
  2.65  10-3 dB
  D)
 
  2.65  10-3 W
  E)
 
  -25.8 dB



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

fauacakatahaias

  • Sr. Member
  • ****
  • Posts: 353
Answer to Question 1

A

Answer to Question 2

A




corkyiscool3328

  • Member
  • Posts: 539
Reply 2 on: Jul 29, 2018
Thanks for the timely response, appreciate it


lkanara2

  • Member
  • Posts: 329
Reply 3 on: Yesterday
Great answer, keep it coming :)

 

Did you know?

Amphetamine poisoning can cause intravascular coagulation, circulatory collapse, rhabdomyolysis, ischemic colitis, acute psychosis, hyperthermia, respiratory distress syndrome, and pericarditis.

Did you know?

Atropine was named after the Greek goddess Atropos, the oldest and ugliest of the three sisters known as the Fates, who controlled the destiny of men.

Did you know?

Interferon was scarce and expensive until 1980, when the interferon gene was inserted into bacteria using recombinant DNA technology, allowing for mass cultivation and purification from bacterial cultures.

Did you know?

The strongest synthetic topical retinoid drug available, tazarotene, is used to treat sun-damaged skin, acne, and psoriasis.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library